LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Teva Pharmaceutical Industries Ltd.

Cerrado

SectorSanidad

34.03 -0.38

Resumen

Variación precio

24h

Actual

Mínimo

34

Máximo

34.2

Métricas clave

By Trading Economics

Ingresos

-112M

369M

Ventas

-730M

4B

P/B

Media del Sector

25.396

49.701

BPA

0.53

Margen de beneficios

9.269

Empleados

31,173

EBITDA

245M

877M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+24.39% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.2B

40B

Apertura anterior

34.41

Cierre anterior

34.03

Noticias sobre sentimiento de mercado

By Acuity

5%

95%

1 / 345 Clasificación en Healthcare

Teva Pharmaceutical Industries Ltd. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 oct 2025, 09:10 UTC

Acciones populares

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

Comparación entre iguales

Cambio de precio

Teva Pharmaceutical Industries Ltd. previsión

Precio Objetivo

By TipRanks

24.39% repunte

Estimación a 12 Meses

Media 42.38 USD  24.39%

Máximo 50 USD

Mínimo 40 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Teva Pharmaceutical Industries Ltd. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

8

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

1 / 345 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
help-icon Live chat